Login to Your Account



A FULL PIPELINE

HCV drug marketplace poised for growth – investors taking note

By Peter Winter
Editor

Monday, February 10, 2014

About 3 percent of the world’s population has been infected with the hepatitis C virus (HCV) and more than 170 million chronic carriers are at risk of developing serious related diseases such as liver cirrhosis and liver cancer, the World Health Organization estimates. It is not surprising then that the global market for new HCV medicines is poised for dramatic growth.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription